Verrica Pharmaceuticals
VRCA
45 hedge funds and large institutions have $82M invested in Verrica Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 9 closing their positions.
1,533% more call options, than puts
Call options by funds: $49K | Put options by funds: $3K
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
0.08% less ownership
Funds ownership: 3.33% → 3.25% (-0.08%)
8% less funds holding
Funds holding: 49 → 45 (-4)
28% less capital invested
Capital invested by funds: $115M → $82M (-$32.6M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$9.81M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.63M |
| 3 |
BlackRock
New York
|
+$1.69M |
| 4 |
Millennium Management
New York
|
+$879K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$18.5M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.79M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$703K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$229K |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$218K |
VRCA Hedge Fund Activity: Q4 2021 in Review
45 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2021, worth a combined $82M — down 28% from $115M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VRCA and 5 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was Morgan Stanley, adding an estimated $9.81M. The largest seller was OrbiMed, exiting entirely with an estimated $18.5M sold.
- 45 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2021, down from 49 in Q3 2021.
- Funds reported $82M of Verrica Pharmaceuticals stock for Q4 2021, down 28% quarter-over-quarter.
- 5 funds opened new Verrica Pharmaceuticals positions in Q4 2021 and 9 closed out, a net change of -4 holders.
- The largest Verrica Pharmaceuticals buyer in Q4 2021 was Morgan Stanley, an estimated $9.81M added.
- The largest Verrica Pharmaceuticals seller in Q4 2021 was OrbiMed, an estimated $18.5M sold.
Based on aggregated 13F filings for Q4 2021.